abrocitinib
Trade name: Cibinqo
Small moleculeapprovedBreakthrough Therapy FDA
Approved
Jan 14, 2022
Abrocitinib, sold under the brand name Cibinqo, is a medication used for the treatment of atopic dermatitis (eczema). It is a Janus kinase inhibitor and it was developed by Pfizer. It is taken by mouth. — Wikipedia
Clinical trial activity
19 trials · 11 clinical orgs · 1 marketing orgs
Phase 1
4
Phase 2
12
Phase 3
5
Phase 4
1
Earliest trial started Mar 8, 2018 (NCT03422822)
Timeline
Indications
Approved for
Studied for
- Alopecia Areata · Phase 2
- Dermatitis, Atopic · Phase 4
- Diabetes Mellitus, Type 1 · Phase 2
- Eczema · Phase 3
- Fatigue Syndrome, Chronic · Phase 2
- Food Hypersensitivity · Phase 1
- Granuloma Annulare · Phase 2
- Healthy Volunteers · Phase 1
- Prurigo · Phase 2
- Pruritus · Phase 2
- Sarcoidosis · Phase 2
- Skin Diseases · Phase 2
- Stevens-Johnson Syndrome · Early Phase 1
Mechanism of action
- Jak1 proteinANTAGONIST
JAK1 antagonist
- Tyrosine-protein kinase JAK1INHIBITOR
Tyrosine-protein kinase JAK1 inhibitor
Approval history
- approvedPriority reviewBreakthroughJan 14, 2022
Chemistry & pharmacology
Loading structure…
SMILES
CCCS(=O)(=O)N[C@H]1C[C@@H](N(C)c2ncnc3[nH]ccc23)C1- Mol. weight
- 323.42 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Delivery
- Oral
- Availability
- Prescription Only
Oral
Yes
Parenteral
No
Topical
No
Black box warning
Sources
- WikipediaAbrocitinib ↗
- ChEMBLCHEMBL3655081 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07242638 | Phase 2 | Jan 5, 2026 | Columbia University, Icahn School of Medicine at Mount Sinai, National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) |
| NCT06807281 | Phase 3 | Nov 3, 2025 | Pfizer |
| NCT06807268 | Phase 3 | Jun 16, 2025 | Pfizer |
| NCT06597396 | Phase 2 | Dec 27, 2024 | Harvard University, Pfizer |
| NCT06283550 | Phase 2 | May 31, 2024 | Innovaderm |
| NCT05743244 | Phase 2 | Oct 19, 2023 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer |
| NCT06119490 | Early Phase 1 (Phase 1) | Jul 5, 2023 | Fujian Provincial Hospital |
| NCT05696795 | Phase 2 | Jun 1, 2023 | Pfizer, Yale University |
| NCT05650736 | Phase 2 | Feb 1, 2023 | Pfizer, Yale University |
| NCT05602207 | Phase 4 | Nov 25, 2022 | Innovaderm |
| NCT05375929 | Phase 3 | Jul 16, 2022 | Pfizer |
| NCT05069831 | Phase 1 | Jan 31, 2022 | Icahn School of Medicine at Mount Sinai |
| NCT05067439 | Phase 1 | Oct 21, 2021 | Pfizer |
| NCT05038982 | Phase 2 | Sep 9, 2021 | Duke University, Johns Hopkins University, Pfizer |
| NCT04903093 | Phase 1 | Jun 4, 2021 | Pfizer |
| NCT04345367 | Phase 3 | Apr 30, 2020 | Pfizer |
| NCT03422822 | Phase 3 | Mar 8, 2018 | Pfizer |
| NCT05466578 | N/A | — | Pfizer |
| NCT04564755 | N/A | — | Pfizer |
Showing 19 of 19 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 14 | 9 | 4 | 2018 |
| Icahn School of Medicine at Mount Sinai | Academic/Hospital | 2 | 2 | 2 | 2022 |
| Innovaderm | For profit | 2 | 2 | 2 | 2022 |
| Yale University | Academic/Hospital | 2 | 2 | 1 | 2023 |
| Columbia University | Academic/Hospital | 1 | 0 | 1 | 2026 |
| Duke University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| Fujian Provincial Hospital | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Johns Hopkins University | Academic/Hospital | 1 | 1 | 1 | 2021 |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) | Government | 1 | 0 | 1 | 2026 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Government | 1 | 1 | 1 | 2023 |
11 organizations
Page 1 / 1